These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27196668)

  • 1. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
    Yalon M; Tuval-Kochen L; Castel D; Moshe I; Mazal I; Cohen O; Avivi C; Rosenblatt K; Aviel-Ronen S; Schiby G; Yahalom J; Amariglio N; Pfeffer R; Lawrence Y; Toren A; Rechavi G; Paglin S
    PLoS One; 2016; 11(5):e0155711. PubMed ID: 27196668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.
    Soung YH; Chung J
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.
    Tuval-Kochen L; Paglin S; Keshet G; Lerenthal Y; Nakar C; Golani T; Toren A; Yahalom J; Pfeffer R; Lawrence Y
    PLoS One; 2013; 8(10):e77260. PubMed ID: 24204783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
    Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
    Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
    Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
    Ning J; Wakimoto H
    Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
    Choi YE; Park E
    J Nutr Biochem; 2015 Dec; 26(12):1442-7. PubMed ID: 26350251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.